Mugnaini M, Antolini M, Corsi M, van Amsterdam F T
Glaxo Wellcome S.p.A., Medicines Research Centre, Verona, Italy.
J Recept Signal Transduct Res. 1998 Mar-May;18(2-3):91-112. doi: 10.3109/10799899809047739.
Binding of [3H]5,7-dichlorokynurenic acid ([3H]DCKA), a competitive antagonist of the strychnine-insensitive glycine site of the N-methyl-D-aspartate (NMDA) receptor channel complex, was characterized in synaptic plasma membranes from rat cerebral cortex. Non linear curve fitting of [3H]DCKA saturation and homologous displacement isotherms indicated the existence of two binding sites: a specific, saturable, high affinity site, with a pKD value of 7.24 (KD = 57.5 nmol/l) and a maximum binding value (Bmax) of 6.9 pmol/mg of protein and a second site, with micromolar affinity. The pharmacological profile of both binding components was determined by studying the effect on [3H]DCKA and [3H]glycine binding of a series of compounds known to interact with different excitatory and inhibitory amino acid receptors. These studies confirmed the identity of the high affinity site of [3H]DCKA binding with the strychnine-insensitive glycine site of the NMDA receptor channel complex. 3-[2-(Phenylaminocarbonyl)ethenyl]-4,6-dichloroindole-2-carb oxylic acid sodium salt (GV 150526A), a new, high affinity, selective glycine site antagonist (1), was the most potent inhibitor of this component of binding (pKi = 8.24, Ki = 5.6 nmol/l). The low affinity component of [3H]DCKA binding was insensitive to the agonists glycine and D-serine and the partial agonist (+/-)-3-amino-1-hydroxy-2-pyrrolidone (HA 966), though recognised by glycine site antagonists. The precise nature of this second, low affinity [3H]DCKA binding site remains to be elucidated.
N-甲基-D-天冬氨酸(NMDA)受体通道复合物中士的宁不敏感型甘氨酸位点的竞争性拮抗剂[3H]5,7-二氯犬尿喹啉酸([3H]DCKA)与大鼠大脑皮层突触质膜的结合特性进行了研究。[3H]DCKA饱和及同源置换等温线的非线性曲线拟合表明存在两个结合位点:一个特异性、可饱和的高亲和力位点,pKD值为7.24(KD = 57.5 nmol/L),最大结合值(Bmax)为6.9 pmol/mg蛋白质;另一个位点具有微摩尔亲和力。通过研究一系列已知与不同兴奋性和抑制性氨基酸受体相互作用的化合物对[3H]DCKA和[3H]甘氨酸结合的影响,确定了两个结合成分的药理学特征。这些研究证实了[3H]DCKA结合的高亲和力位点与NMDA受体通道复合物中士的宁不敏感型甘氨酸位点一致。新型高亲和力选择性甘氨酸位点拮抗剂3-[2-(苯氨基羰基)乙烯基]-4,6-二氯吲哚-2-羧酸(GV 150526A)是该结合成分最有效的抑制剂(pKi = 8.24,Ki = 5.6 nmol/L)。[3H]DCKA结合的低亲和力成分对激动剂甘氨酸和D-丝氨酸以及部分激动剂(±)-3-氨基-1-羟基-2-吡咯烷酮(HA 966)不敏感,不过能被甘氨酸位点拮抗剂识别。第二个低亲和力[3H]DCKA结合位点的确切性质仍有待阐明。